Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Budde

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2022
Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALLIbrahim Aldoss, Samer K Khaled, Xiuli Wang, et al.
Transplantation and Cellular Therapy|July 10, 2026
Impact of prior CAR T-cell treatment on graft-vs-host disease and non-relapse mortality after allogeneic transplantationTamer Othman, Dongyun Yang, Geoffrey Shouse, et al.
Nature Medicine|December 10, 2023
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trialLihua E Budde, Adam J Olszewski, Sarit Assouline, et al.
Blood|April 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 studyLihua E Budde, Manali Kamdar, Sarit E Assouline, et al.
Blood Advances|April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphomaNancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.
Blood Advances|October 8, 2025
Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetrationLei Gao, Avyakta Kallam, Geoffrey Shouse, et al.
Blood|April 28, 2016
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHLXiuli Wang, Leslie L Popplewell, Jamie R Wagner, et al.
Blood Advances|November 10, 2025
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative AnalysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Cancer Immunology Research|October 23, 2020
The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic LymphomaXiuli Wang, Christian Huynh, Ryan Urak, et al.
Cancer Discovery|April 7, 2024
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell CarcinomaSumanta K Pal, Ben Tran, John B A G Haanen, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2022
Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALLIbrahim Aldoss, Samer K Khaled, Xiuli Wang, et al.
Transplantation and Cellular Therapy|July 10, 2026
Impact of prior CAR T-cell treatment on graft-vs-host disease and non-relapse mortality after allogeneic transplantationTamer Othman, Dongyun Yang, Geoffrey Shouse, et al.
Nature Medicine|December 10, 2023
Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trialLihua E Budde, Adam J Olszewski, Sarit Assouline, et al.
Blood|April 21, 2026
Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 studyLihua E Budde, Manali Kamdar, Sarit E Assouline, et al.
Blood Advances|April 17, 2023
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphomaNancy L Bartlett, Sarit Assouline, Pratyush Giri, et al.
Blood Advances|October 8, 2025
Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetrationLei Gao, Avyakta Kallam, Geoffrey Shouse, et al.
Blood|April 28, 2016
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHLXiuli Wang, Leslie L Popplewell, Jamie R Wagner, et al.
Blood Advances|November 10, 2025
A Phase I Study of Blinatumomab/Lenalidomide in Relapsed/Refractory B cell Lymphoma; Toxicity, Efficacy and Correlative AnalysisJoseph M Tuscano, Tamer Othman, Paul Frankel, et al.
Cancer Immunology Research|October 23, 2020
The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic LymphomaXiuli Wang, Christian Huynh, Ryan Urak, et al.
Cancer Discovery|April 7, 2024
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell CarcinomaSumanta K Pal, Ben Tran, John B A G Haanen, et al.
Pageof 10